Recently, Holmberg et al reported on a strikingly high incidence of cytomegalovirus (CMV) infection and disease in a cohort of patients receiving high-dose chemotherapy followed by the infusion of autologous CD34-selected peripheral blood progenitor cell transplants (PBPCTs). In a multivariate logistic regression analysis, the use of CD34-selected autologous peripheral blood stem cells after high-dose therapy was associated with a marked increase in the incidence of CMV disease and CMV-associated deaths.1 

Here we report the incidence of CMV infection and disease following allogeneic stem cell transplantation comparing recipients of(a) unmanipulated allogeneic peripheral blood stem cells from HLA-identical siblings (group I), (b) CD34-selected allogeneic peripheral blood stem cells from HLA-identical (n = 15) or 1 Antigen-mismatch (n = 3) siblings (group II), and (c) a group of patients receiving in vivo T-cell depleted bone marrow from HLA-identical (n = 11) or 1 Antigen-mismatch (n = 4) unrelated donors (group III). Patient characteristics for the 3 groups are shown in Table 1. The Cellpro Ceprate System (Cellpro, Seattle, WA) was used in all cases of group II to select CD34+ cells. The median number of CD34+cells/kg body weight (bw) was not different between groups I and II (4.17 ± 0.53 × 106 versus 3.96 ± 1.05 × 106). CD34+ selection resulted in a reduction of CD3+ cells from 188.1 ± 76.9 × 106 cells/kg bw (group I, n = 17) to 0.39 ± 0.24 × 106 cells/kg bw (group II, n = 18). Graft-versus-host disease (GVHD)–prophylaxis consisted of cyclosporine A (CSA) (all patients) plus methotrexate (group I, n = 6; group II, n = 4) or antithymocyte globulin (ATG; Biomerieux, Paris, France) on days − 4 to − 2 at a dose of 2.5 mg/kg bw (group I, n = 10; group II, n = 2). Patients in group III received transplants from unrelated donors and received an intensified graft-versus-host prophylaxis regimen (German multicenter study) incorporating antithymocyte globulin (Biomerieux) at a dose of 3.5 mg/kg bw on days − 4 to − 1, CSA in a dose of 5 mg/kg bw (dose adjustment according to serum levels), methylprednisolone at 0.5 mg/kg bw on days +7 to +14 and at 1 mg/kg bw from days +14 to +28, and mycophenolate mofetil starting on day +7 after bone marrow transplantation (BMT).

All patients were monitored by a polymerase chain reaction (PCR)–assay once weekly and received preemptive antiviral therapy with ganciclovir at 2 × 5mg/kg bw or foscarnet at 2 × 60 mg/kg bw as reported previously.2 

Overall, 12 of 19 patients receiving unmanipulated peripheral blood stem cells developed CMV infection after transplantation, compared to 16 of 18 receiving CD34-selected stem cells and 15 of 15 after BMT from an unrelated donor (group I versus group II, P = .12; group I versus group III, P = .01) (Table 1). The time to the first positive PCR result after transplantation was observed at a median of 29.5 (3-44) days in group I, 24.5 (5-46) days in group II, and 21 (8-33) days in group III (for group I versus group III,P = 0.01, Wilcoxon rank test) (Figure1). The time to clearance of viral DNA in the blood after the initiation of antiviral therapy did not differ between groups I and II (3.3 [0-10] weeks and 3.3 [0-10] weeks, respectively), whereas it was significantly longer in patients after BMT from an unrelated donor receiving an intensified GVHD-prophylaxis regimen (median duration of DNAemia, 8.7 [range 2-18] weeks,P = .0002, Wilcoxon rank test). CMV disease was documented in 1 patient receiving unmanipulated allogeneic stem cells (fatal CMV pneumonia), in 2 patients receiving CD34-selected stem cells (fatal CMV pneumonia, n = 1; enteritis after day 100 after transplantation, n = 1), and in 3 patients following BMT from an unrelated donor accompanied by intensified GVHD prophylaxis (fatal IP, n = 1; hepatitis, n = 1; late onset retinitis, n = 1).

Fig. 1.

Time to CMV infection after stem cell transplantation.

The figure shows the time to the first positive PCR result. The time to the first positive PCR result after transplantation was observed at a median of 29.5 [3-44] days in group I, 24.5 [5-46] days in group II, and 21 [8-33] days in group III (for group I versus group III,P = .01, Wilcoxon rank test). ▵, allogeneic peripheral blood stem cell transplantation (group I); ⋄, CD34+-selected allogeneic peripheral blood stem cell transplantation (group II); and ○, bone marrow transplantation from an unrelated donor (in vivo T-cell depletion) (group III).

Fig. 1.

Time to CMV infection after stem cell transplantation.

The figure shows the time to the first positive PCR result. The time to the first positive PCR result after transplantation was observed at a median of 29.5 [3-44] days in group I, 24.5 [5-46] days in group II, and 21 [8-33] days in group III (for group I versus group III,P = .01, Wilcoxon rank test). ▵, allogeneic peripheral blood stem cell transplantation (group I); ⋄, CD34+-selected allogeneic peripheral blood stem cell transplantation (group II); and ○, bone marrow transplantation from an unrelated donor (in vivo T-cell depletion) (group III).

Close modal

The median numbers of CD3+ and CD8+ lymphocytes per microliter of blood assessed at 3 and 6 months after transplantation did not differ among the 3 groups. But reconstitution of CD4+ T cells at 3 months was significantly delayed in patients receiving bone marrow from unrelated donors compared to patients receiving CD34+-selected allogeneic stem cells (median 26, range 2-770 CD4+ T cells/μL versus a median of 186, range 42-350 CD4+ T cells/μL,P = .01, Wilcoxon rank test; see Table2), and at 3 months in patients developing CMV disease (median 4, range 2-65 CD4+ T cells/μL, n = 3) compared to patients with asymptomatic CMV infection (median 70, range 5-770 CD4+ T cells/μL, n = 25) or without signs of CMV reactivation (median 100, range 49-350 CD4+ T cells/μL, n = 5) (P = .08, Wilcoxon rank test).

CMV infection was diagnosed by PCR in all patients prior to the onset of CMV-related clinical symptoms. But in 1 patient receiving CD34-selected stem cells, CMV-IP developed before a second positive PCR result was obtained 1 week later, indicating that the time from the first positive PCR result to the onset of clinical symptoms might be very short in patients receiving T-cell–depleted allografts. Thus patients receiving CD34-selected allogeneic stem cells from related donors may develop CMV infection quite soon after transplantation. But due to a rapid immune reconstitution and early initiation of antiviral therapy based on a PCR assay, no increase in CMV-related morbidity and mortality after CD34+-selected allogeneic stem cell transplantation was observed. Patients receiving bone marrow from unrelated donors followed by an intensified GVHD prophylaxis showed CMV PCR positivity even sooner after transplantation, but again PCR-based antiviral therapy was found to be safe with only 1 patient developing early fatal CMV disease as already reported previously.2But this group seemed to be at an increased risk for late onset CMV disease most likely due to a delayed reconstitution of CMV-specific T-cell responses.3-5 

In conclusion, as discussed by Holmberg et al and demonstrated in this study, the high incidence of CMV disease in recipients of CD34-selected stem cells can be reduced by the early initiation of preemptive antiviral therapy based on sensitive assays,1,6 but probably to the expense of an increased incidence of late-onset CMV disease, especially in patients with delayed immune reconstitution.7-9 

Supported by the Sonderforschungsbereich 510, project B3, and the IZKF Tübingen, project IIC2.

1
Holmberg
LA
Boeckh
M
Hooper
H
et al
Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation.
Blood.
94
1999
4029
4035
2
Einsele
H
Ehninger
G
Hebart
H
et al
Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation.
Blood.
86
1995
2815
2820
3
Krause
H
Hebart
H
Jahn
G
Müller
CA
Einsele
H
Screening for CMV-specific T cell proliferation to identify patients at risk of developing late onset CMV disease.
Bone Marrow Transplant.
19
1997
1111
1116
4
Small
TN
Papadopoulos
EB
Boulad
F
et al
Comparison of immune reconstitution after unrelated and related T-cell–depleted bone marrow transplantation: effect of patient age and donor leukocyte infusions.
Blood.
93
1999
467
480
5
Li
CR
Greenberg
PD
Gilbert
KJ
Goodrich
JM
Riddell
SR
Recovery of HLA-restricted cytomegalovirus responses after allogeneic bone marrow transplantation: correlation with CMV disease and effect of ganciclovir prophylaxis.
Blood.
83
1994
1971
1979
6
Hebart
H
Schroeder
A
Loeffler
J
et al
Cytomegalovirus monitoring by polymerase chain reaction of whole blood samples from patients undergoing autologous bone marrow or peripheral blood progenitor cell transplantation.
J Infect Dis.
175
1997
1490
1493
7
Boeckh
M
Riddell
SR
Cunningham
T
Myerson
D
Flowers
M
Bowden
RA
Increased risk of late CMV infection and disease in allogeneic marrow transplant recipients after ganciclovir prophylaxis is due to a lack of CMVspecific T-cell responses.
Blood.
88(suppl 1)
1996
643a
8
Einsele
H
Hebart
H
Kauffmann-Schneider
C
et al
Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection.
Bone Marrow Transplant.
25
2000
757
763
9
Nguyen
Q
Champlin
R
Giralt
S
et al
Late cytomegalovirus pneumonia in adult allogeneic blood and marrow transplant recipients.
Clin Infect Dis.
28
1999
618
623
Sign in via your Institution